Aripiprazole Tablet
Product Images NDC 70518-2584

15 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2584). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description Image (Structure)

Description Image (Structure)
Chemical structure of aripiprazole, illustrating the molecular arrangement of its atoms and bonds, including chlorinated aromatic rings, a piperazine ring, and an indolinone core.*
FDA Label Image

Image 1 (Figure 1)

Image 1 (Figure 1)
A pharmacokinetic chart titled 'The Effect of Other Drugs on Aripiprazole Pharmacokinetics' showing the fold change and 90% confidence interval of aripiprazole's AUC and Cmax when co-administered with various drugs. The x-axis represents the change relative to reference (without interacting drug), ranging from 0 to 3. Drugs listed include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and others like valproate, lithium, and lorazepam.*
FDA Label Image

Image 2 (Figure 2)

Image 2 (Figure 2)
A chart titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold changes and 90% confidence intervals for AUC and Cmax parameters. The chart compares the impact of various drugs, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam, on dehydro-aripiprazole pharmacokinetics relative to a reference without interacting drug.*
FDA Label Image

Image 3 (Figure 3)

Image 3 (Figure 3)
A scatter plot illustrating the effect of aripiprazole on the pharmacokinetics of various drugs. The vertical axis lists drugs such as dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, and venlafaxine, with PK parameters like AUC and Cmax shown. The horizontal axis displays fold change relative to reference, indicating drug interaction impact with 90% confidence intervals.*
FDA Label Image

Image 4 (Figure 4)

Image 4 (Figure 4)
A chart titled 'Effect of Intrinsic Factors on Aripiprazole Pharmacokinetics' showing fold changes with 90% confidence intervals for aripiprazole's AUC and Cmax across different special populations and intrinsic factors, including CYP2D6 metabolism status, gender, age, hepatic impairment levels, and severe renal impairment. The horizontal axis indicates change relative to reference values.*
FDA Label Image

Image 5 (Figure 5)

Image 5 (Figure 5)
A pharmacokinetic chart titled 'Effect of Intrinsic Factors on Dehydro-aripiprazole Pharmacokinetics' showing fold changes and 90% confidence intervals for various intrinsic factors such as CYP2D6 metabolizer status, gender, age groups, and degrees of hepatic and renal impairment. The x-axis represents change relative to reference, and the y-axis lists these intrinsic factors with pharmacokinetic parameters AUC and Cmax compared across groups.*
FDA Label Image

Fig-6 (Figure 6)

Fig-6 (Figure 6)
Kaplan-Meier curve chart estimating the cumulative proportion of patients with relapse over time in a schizophrenia study. The x-axis represents days from randomization (0 to 182), and the y-axis shows proportion with relapse (0 to 1.0). Two survival curves compare Aripiprazole and placebo groups, with numbers of subjects at risk listed below the x-axis over time.*
FDA Label Image

7 (Figure 7)

7 (Figure 7)
Kaplan-Meier plot showing the cumulative proportion of patients with relapse over days from randomization in a Bipolar Study 7. The graph compares aripiprazole and placebo groups, with proportion of relapse on the Y-axis and time in days on the X-axis. A table below the graph shows the number of subjects at risk for each group at various time points.*
FDA Label Image

8 (Figure 8)

8 (Figure 8)
Kaplan-Meier curve illustrating the cumulative proportion of patients experiencing relapse to any mood event over days from randomization in a bipolar study. The graph compares relapse proportions between aripiprazole and placebo groups, with corresponding patient counts at risk shown below the x-axis.*
FDA Label Image

9 (Figure 9)

9 (Figure 9)
A line graph showing the least squares mean change from baseline in YGTSS total tic score over 8 weeks of treatment. Three lines represent aripiprazole low dose, aripiprazole high dose, and placebo groups, with both aripiprazole doses showing greater reductions in tic score compared to placebo over time.*
FDA Label Image

Mm1 (Aripiprazole 2mg 70518 2584 00)

Mm1 (Aripiprazole 2mg 70518 2584 00)
Label for Aripiprazole tablet 2 mg, packaged in a quantity of 30 tablets. The label includes dosage strength, package count, NDC number 70518-2584-00, and physical description as round yellow tablets. Repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and usual dosage note are also visible.*
FDA Label Image

Mm2 (Aripiprazole 2mg 70518 2584 01)

Mm2 (Aripiprazole 2mg 70518 2584 01)
Aripiprazole 2 mg tablet packaging label showing quantity of 180 tablets. The label includes NDC number 70518-2584-01 and indicates the product is repackaged by RemedyRepack Inc. Directions note to see package insert. The label also includes storage temperature guidelines and a QR code, with the manufacturer listed as Torrent, Bharuch, India.*
FDA Label Image

Mm3 (Aripiprazole 2mg 70518 2584 02)

Mm3 (Aripiprazole 2mg 70518 2584 02)
Aripiprazole tablet 2 mg oral dosage form, repackaged by RemedyRepack Inc. The box contains 100 tablets. The label includes storage instructions and manufacturer information (Torrent, India). The tablets are described as round and yellow.*
FDA Label Image

Mm4 (Aripiprazole 2mg 70518 2584 03)

Mm4 (Aripiprazole 2mg 70518 2584 03)
Label for aripiprazole 2 mg oral tablet, with a quantity of 1 tablet. The label includes the NDC number 70518-2584-03 and notes the tablet is round and yellow. It is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and manufacturer details from Torrent, India, are also present.*
FDA Label Image

Mm5 (Aripiprazole 2mg 70518 2584 04)

Mm5 (Aripiprazole 2mg 70518 2584 04)
Aripiprazole Tablet 2 mg oral tablets in a package containing 30 tablets. The label shows the NDC number 70518-2584-04 and indicates the tablets are round and yellow. It is repackaged by RemedyRepack Inc., located in Indiana, PA. Storage instructions and safety warnings are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.